The market is expanding due to growing demand for improved drug solubility and advanced controlled-release formulations. Rising use of continuous, solvent-free manufacturing technologies is further celebrating market adoption.
Pharmaceutical hot melt extrusion is a continuous drug manufacturing process in which active ingredients and ploymers and blended under heat and pressure to improve drug solubility, stability, and controlled release. continue to support growth. The U.S. pharmaceutical hot melt extrusion market is growing due to rising demand for advanced drug delivery systems that enhance the solubility, bioavailability, and controlled release of poorly water-soluble drugs. Increased investment in domestic pharmaceutical manufacturing, supportive regulatory initiatives, and the expansion of CDMOs are accelerating the adoption of continuous, solvent-free extrusion technologies. Additionally, the push for personalized medicine and innovative dosage forms is driving further market growth.
The global pharmaceutical hot melt extrusion market size was estimated at USD 38.9 billion in 2025 and is predicted to increase from USD 40.76 billion in 2026 to approximately USD 62.11 billion by 2035, expanding at a CAGR of 4.79% from 2026 to 2035
The U.S. pharmaceutical hot melt extrusion market is expected to witness strong future opportunities driven by increasing use in personalized medicine, advanced drug delivery systems, and long-acting formulations. Rising focus on poorly soluble drugs and continuous manufacturing technologies is creating significant scope for innovation and commercial expansion.
| Indicator | 2023 | 2025 |
| Employer establishments in pharmaceutical & medicine manufacturing | 2,905 | 3,150 |
| Monthly Pharmaceutical Shipment | 20.7B | 24.8B |
| Chemical Manufacturing establishments | 14,543 | 14,961 |
Between 2023 and 2025, U.S. pharmaceutical production showed clear expansion, with monthly manufacturing shipments rising from about 20.7 billion to 24.8 billion, reflecting stronger output and demand. The count of domestic chemical manufacturing establishments, which support drug formulation processes, also remained robust, indicating ongoing industrial growth and increased manufacturing activity that strengthens the ecosystem for technologies like hot melt extrusion.
The twin-screw extruder segment dominated the U.S. pharmaceutical hot melt extrusion market with a share of 65% in 2025 due to its superior mixing efficiency, better heat and shear control, and ability to process a wide range of polymers and APIs. Its versatility in producing amorphous solid dispersion, controlled-release formulation, and high-quality pellets makes it the preferred choice for both R&D and commercial-scale production.
The pharma companies segment led the U.S. pharmaceutical hot melt extrusion market with shares of 50% in 2025 due to their strong focus on R&D, advanced formulation development, and large-scale production capabilities. High investment in drug solubility enhancement, controlled-release systems, and continuous manufacturing technologies allows pharma companies to efficiently adopt hot melt extrusion, driving dominance in both research and commercial applications.
The solid dosage forms segment dominated the U.S. pharmaceutical hot melt extrusion market with a share of 70% in 2025 due to their wide acceptance, ease of administration, and compatibility with hot melt extrusion. Tablets and capsules allow precise drug dosing, improved stability, and enhanced bioavailability, making them the preferred choice for both pharmaceutical companies and contract manufacturing organizations.
The pharmaceutical manufacturing segment held a dominant position in the U.S. pharmaceutical hot melt extrusion market with a share of 55% in 2025 due to its large-scale production capacity, strong R&D infrastructure, and expertise in advanced drug formulations. High adoption of hot melt extrusion for improving solubility, bioavailability, and controlled-release profiles, combined with continuous manufacturing practices, reinforces its leading position in the market.
Leading companies in the U.S. pharmaceutical hot melt extrusion market, including Thermo Fisher Scientific, Coperion, Leistritz, and Baker Perkins, dominate with advanced HME systems and formulation solutions. Large pharma and CDMOs drive adoption, while emerging regional players are gaining ground in pilot-scale extrusion and niche drug development, supporting innovation in controlled-release and poorly soluble drug formulations.
By Type
By Application
By Dosage Form
By End-Use
By Region
